Clinical trial
A PHASE 1 STUDY OF PF-05082566 AS A SINGLE AGENT IN PATIENTS WITH ADVANCED CANCER, AND IN COMBINATION WITH RITUXIMAB IN PATIENTS WITH NON-HODGKIN'S LYMPHOMA (NHL)
NCT01307267 is registered in ClinicalTrials.gov with Pfizer as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A PHASE 1 STUDY OF PF-05082566 AS A SINGLE AGENT IN PATIENTS WITH ADVANCED CANCER, AND IN COMBINATION WITH RITUXIMAB IN PATIENTS WITH NON-HODGKIN'S LYMPHOMA (NHL)
- Lead sponsor
- Pfizer
- Phase
- Phase 1
- Overall status
- Completed
- Start date
- June 21, 2011
- Completion date
- February 20, 2019
- Enrollment
- 190 (actual)
- Sites
- 42
Conditions
As the registry lists them; a condition with its own page is linked.
carcinoma, non-small-cell lung, carcinoma, renal cell, carcinoma, squamous cell of head and neck, lymphoma, follicular, lymphoma, large b-cell, diffuse, lymphoma, non-hodgkin, malignant melanoma